Published in J Infect Dis on March 01, 1996
Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol (2002) 3.21
A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ (2006) 3.11
Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol (2001) 2.23
rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol (1998) 1.90
Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol (2006) 1.75
Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol (2001) 1.62
Evaluation of enzyme-linked immunosorbent assays, an immunofluorescent-antibody test, and two rapid tests (immunochromatographic-dipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogs. J Clin Microbiol (2005) 1.46
Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen. Clin Diagn Lab Immunol (2002) 1.41
Rapid detection of Leishmania infantum infection in dogs: comparative study using an immunochromatographic dipstick test, enzyme-linked immunosorbent assay, and PCR. J Clin Microbiol (2002) 1.40
Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India. Am J Trop Med Hyg (2010) 1.34
Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis (2010) 1.28
Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis (2012) 1.26
Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol (2006) 1.26
Comparative evaluation of enzyme-linked immunosorbent assays based on crude and recombinant leishmanial antigens for serodiagnosis of symptomatic and asymptomatic Leishmania infantum visceral infections in dogs. Clin Vaccine Immunol (2007) 1.23
Diagnosis of visceral leishmaniasis: developments over the last decade. Parasitol Res (2011) 1.21
Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol (1997) 1.17
Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection. Genes Immun (2007) 1.14
Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol (1998) 1.13
Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clin Pathol (2003) 1.11
Development of recombinant chimeric antigen expressing immunodominant B epitopes of Leishmania infantum for serodiagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol (2005) 1.09
Evaluation of rK-39 strip test using urine for diagnosis of visceral leishmaniasis in an endemic region of India. Am J Trop Med Hyg (2012) 1.09
Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun (2006) 1.09
Evaluation of rK39 rapid diagnostic tests for canine visceral leishmaniasis: longitudinal study and meta-analysis. PLoS Negl Trop Dis (2013) 1.08
Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J Clin Microbiol (2002) 1.02
Enzyme-linked immunosorbent assay based on soluble promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera from cases of visceral and cutaneous leishmaniasis. J Clin Microbiol (2002) 1.01
Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay. PLoS Negl Trop Dis (2012) 1.01
Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect Immun (1999) 0.99
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine (2010) 0.98
Diagnosis of mediterranean visceral leishmaniasis by detection of leishmania antibodies and leishmania DNA in oral fluid samples collected using an Oracol device. J Clin Microbiol (2011) 0.98
Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol (2008) 0.97
Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of Leishmania DNA in buffy coat from visceral leishmaniasis patients. Parasit Vectors (2012) 0.93
Inaccuracy of enzyme-linked immunosorbent assay using soluble and recombinant antigens to detect asymptomatic infection by Leishmania infantum. PLoS Negl Trop Dis (2009) 0.93
Leishmania major-like antigen for specific and sensitive serodiagnosis of human and canine visceral leishmaniasis. Clin Diagn Lab Immunol (2002) 0.93
Evaluation of rK28 antigen for serodiagnosis of visceral Leishmaniasis in India. Clin Microbiol Infect (2011) 0.93
In search of an ideal test for diagnosis and prognosis of kala-azar. J Health Popul Nutr (2010) 0.93
Application of an improved enzyme-linked immunosorbent assay method for serological diagnosis of canine leishmaniasis. J Clin Microbiol (2010) 0.92
rKLO8, a novel Leishmania donovani - derived recombinant immunodominant protein for sensitive detection of visceral leishmaniasis in Sudan. PLoS Negl Trop Dis (2013) 0.91
Evaluation of enzyme-linked immunosorbent assay for diagnosis of post-kala-azar dermal leishmaniasis with crude or recombinant k39 antigen. Clin Diagn Lab Immunol (2002) 0.90
Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach. PLoS Negl Trop Dis (2012) 0.90
Potential of direct agglutination test based on promastigote and amastigote antigens for serodiagnosis of post-kala-azar dermal leishmaniasis. Clin Diagn Lab Immunol (2005) 0.89
Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. Clin Vaccine Immunol (2006) 0.88
Case series of misdiagnosis with rK39 strip test in Indian leishmaniasis. Am J Trop Med Hyg (2011) 0.88
Characterization of novel Leishmania infantum recombinant proteins encoded by genes from five families with distinct capacities for serodiagnosis of canine and human visceral leishmaniasis. Am J Trop Med Hyg (2011) 0.87
Rapid immunochromatographic test for serodiagnosis of canine leishmaniasis. J Clin Microbiol (2004) 0.87
Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts. Clin Vaccine Immunol (2009) 0.86
Cutaneous and presumed visceral leishmaniasis in a soldier deployed to Afghanistan. MedGenMed (2006) 0.84
CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antimicrob Agents Chemother (2011) 0.84
A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward? PLoS Negl Trop Dis (2014) 0.84
Quantification of the natural history of visceral leishmaniasis and consequences for control. Parasit Vectors (2015) 0.84
Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi. Am J Trop Med Hyg (2012) 0.83
Proteomic approach for characterization of immunodominant membrane-associated 30- to 36-kiloDalton fraction antigens of Leishmania infantum promastigotes, reacting with sera from Mediterranean visceral leishmaniasis patients. Clin Diagn Lab Immunol (2005) 0.82
Comparative evaluation of blood and serum samples in rapid immunochromatographic tests for visceral leishmaniasis. J Clin Microbiol (2013) 0.81
Performance of rK39 immunochromatography and freeze-dried direct agglutination tests in the diagnosis of imported visceral leishmaniasis. Parasitol Res (2011) 0.80
rK39 antigen for the diagnosis of visceral leishmaniasis by using human saliva. Am J Trop Med Hyg (2012) 0.79
Leishmaniasis at the End of the Millennium. Curr Infect Dis Rep (1999) 0.78
ELISA and western blotting for the detection of Hsp70 and Hsp83 antigens of Leishmania donovani. J Parasit Dis (2012) 0.78
Infection with Leishmania (Leishmania) infantum of 0 to 18-Month-old children living in a visceral leishmaniasis-endemic area in Brazil. Am J Trop Med Hyg (2014) 0.77
The shadows of a ghost: a survey of canine leishmaniasis in Presidente Prudente and its spatial dispersion in the western region of São Paulo state, an emerging focus of visceral leishmaniasis in Brazil. BMC Vet Res (2015) 0.77
The efficacy of L. (L.) chagasi excreted-secreted antigens (ESAs) for visceral leishmaniasis diagnosis is due to low levels of cross-reactivity. Am J Trop Med Hyg (2013) 0.76
Immunogenicity in dogs and protection against visceral leishmaniasis induced by a 14kDa Leishmania infantum recombinant polypeptide. Trials Vaccinol (2015) 0.75
Synthetic Peptides as Potential Antigens for Cutaneous Leishmaniosis Diagnosis. J Immunol Res (2017) 0.75
Evaluation of an enzyme-linked immunosorbent assay based on crude Leishmania histone proteins for serodiagnosis of human infantile visceral leishmaniasis. Clin Vaccine Immunol (2012) 0.75
Enhancement of experimental cutaneous leishmaniasis by Leishmania extract: identification of a disease-associated antibody specificity. BMC Res Notes (2015) 0.75
Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs. Iran Biomed J (2016) 0.75
Anti-leishmania infantum IgG antibody avidity in visceral leishmaniasis. Clin Vaccine Immunol (2013) 0.75
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 12.29
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA (1998) 5.20
Genetic variation of Drosophila melanogaster natural populations. Trends Genet (1988) 4.62
Suppression of delayed hypersensitivity in vitro by inhibition of protein synthesis. J Exp Med (1965) 4.62
The enhancement of macrophage bacteriostasis by products of activated lymphocytes. J Exp Med (1973) 4.51
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
An in vitro assay for cellular hypersensitivity in man. J Immunol (1970) 3.73
Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science (1992) 3.71
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators. Prog Allergy (1972) 3.47
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A (1993) 3.40
Macrophage migration. Fed Proc (1990) 3.39
Studies on mediator production by highly purified human T and B lymphocytes. J Exp Med (1974) 3.38
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med (1999) 3.23
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Studies on migration inhibitory factor (MIF): recovery of MIF activity after purification by gel filtration and disc electrophoresis. Cell Immunol (1970) 2.86
Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.84
Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.81
Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol (1979) 2.81
Preferential Mating versus Mimicry: Disruptive Selection and Sex-limited Dimorphism in Papilio glaucus. Science (1966) 2.69
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med (1990) 2.67
Cellular sensitivity to collagen in rheumatoid arthritis. N Engl J Med (1978) 2.50
Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol (1995) 2.37
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med (1989) 2.30
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1989) 2.24
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology (2004) 2.20
The compartmentalization of antigen-reactive lymphocytes in desensitized guinea pigs. J Exp Med (1971) 2.18
Metabolic and functonal studies on activated mouse macrophages. J Exp Med (1973) 2.17
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Antibody-dependent eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: damage by purieid eosinophils. J Exp Med (1977) 2.06
Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med (1998) 2.06
Macrophage activation by lymphocyte mediators. Fed Proc (1975) 1.99
Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg (1998) 1.99
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
Host-plant specialization in the Drosophila melanogaster species complex: a physiological, behavioral, and genetical analysis. Proc Natl Acad Sci U S A (1991) 1.98
Similarities and differences in latitudinal adaptation of two Drosophila sibling species. Nature (1975) 1.96
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun (1996) 1.93
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A (1986) 1.93
Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis (2005) 1.91
Evolution in a cosmopolitan species: genetic latitudinal clines in Drosophila melanogaster wild populations. Experientia (1975) 1.91
Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90
Immunochemical studies on the specificity of cellular hypersensitivity. The in vitro inhibition of peritoneal exudate cell migration by cehmically defined antigens. J Exp Med (1968) 1.90
rK39 enzyme-linked immunosorbent assay for diagnosis of Leishmania donovani infection. Clin Diagn Lab Immunol (1998) 1.90
Monoclonal antibodies that distinguish between New World species of Leishmania. Nature (1981) 1.89
Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis (1987) 1.87
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Murine thymocytes proliferate in direct response to interleukin-7. Blood (1989) 1.86
Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology (2009) 1.83
Characterization of migration inhibitory factor (MIF) from guinea pig lymphocytes stimulated with concanavalin A. J Immunol (1972) 1.82
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med (1995) 1.81
Mediators produced by sensitized lymphocytes. Fed Proc (1972) 1.79
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
Mitochondrial DNA variability in Drosophila simulans: quasi absence of polymorphism within each of the three cytoplasmic races. Heredity (Edinb) (1988) 1.76
Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol (2001) 1.74
Activation of human blood monocytes by products of sensitized lymphocytes. J Clin Invest (1974) 1.73
Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg (1991) 1.71
Maternal-fetal relation. Absence of an immunologic blocking factor from the serum of women with chronic abortions. N Engl J Med (1976) 1.69
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol (1982) 1.66
Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol (2000) 1.66
Immunopathology of experimental cutaneous leishmaniasis. Am J Pathol (1984) 1.65
Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. Am J Trop Med Hyg (1987) 1.65
Prevention of MIF activity by agents known to increase cellular cyclic AMP. J Immunol (1973) 1.64
Transfer of cellular hypersensitivity in chronic mucocutaneous candidiasis monitored in vivo and in vitro. Cell Immunol (1970) 1.64
In vivo and in vitro characterization of murine T-cell clones reactive to Mycobacterium tuberculosis. Infect Immun (1987) 1.63
Characterization of human migration inhibitory factor (MIF) from antigen-stimulated lymphocytes. Cell Immunol (1972) 1.63
An improved serodiagnostic procedure for visceral leishmaniasis. Am J Trop Med Hyg (1990) 1.61
Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med (2000) 1.60
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report. Braz J Infect Dis (2001) 1.54
Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A (1981) 1.54
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun (1998) 1.53
Lymphocyte mediators and cellular hypersensitivity. N Engl J Med (1973) 1.53
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Schistosoma mansoni. Anti-egg monoclonal antibodies protect against cercarial challenge in vivo. J Exp Med (1984) 1.51
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun (2001) 1.51
Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia. N Engl J Med (1980) 1.50
Regulation of T cell proliferation by IL-7. J Immunol (1990) 1.50
Genetics of morphological differences and hybrid sterility between Drosophila sechellia and its relatives. Genet Res (1991) 1.49